Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis.

Détails

Ressource 1Télécharger: BIB_14B4AEA9711E.P001.pdf (6973.78 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_14B4AEA9711E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis.
Périodique
Plos One
Auteur⸱e⸱s
Vala Ines Sofia, Martins Leila R., Imaizumi Natsuko, Nunes Raquel J., Rino Jose, Kuonen Francois, Carvalho Lara M., Ruegg Curzio, Grillo Isabel Monteiro, Barata Joao Taborda, Mareel Marc, Rosa Santos Susana Constantino
ISSN
1932-6203[electronic], 1932-6203[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
5
Numéro
6
Pages
11222
Langue
anglais
Notes
epublish
Résumé
Radiotherapy is a widely used treatment option in cancer. However, recent evidence suggests that doses of ionizing radiation (IR) delivered inside the tumor target volume, during fractionated radiotherapy, can promote tumor invasion and metastasis. Furthermore, the tissues that surround the tumor area are also exposed to low doses of IR that are lower than those delivered inside the tumor mass, because external radiotherapy is delivered to the tumor through multiple radiation beams, in order to prevent damage of organs at risk. The biological effects of these low doses of IR on the healthy tissue surrounding the tumor area, and in particular on the vasculature remain largely to be determined. We found that doses of IR lower or equal to 0.8 Gy enhance endothelial cell migration without impinging on cell proliferation or survival. Moreover, we show that low-dose IR induces a rapid phosphorylation of several endothelial cell proteins, including the Vascular Endothelial Growth Factor (VEGF) Receptor-2 and induces VEGF production in hypoxia mimicking conditions. By activating the VEGF Receptor-2, low-dose IR enhances endothelial cell migration and prevents endothelial cell death promoted by an anti-angiogenic drug, bevacizumab. In addition, we observed that low-dose IR accelerates embryonic angiogenic sprouting during zebrafish development and promotes adult angiogenesis during zebrafish fin regeneration and in the murine Matrigel assay. Using murine experimental models of leukemia and orthotopic breast cancer, we show that low-dose IR promotes tumor growth and metastasis and that these effects were prevented by the administration of a VEGF receptor-tyrosine kinase inhibitor immediately before IR exposure. These findings demonstrate a new mechanism to the understanding of the potential pro-metastatic effect of IR and may provide a new rationale basis to the improvement of current radiotherapy protocols.
Mots-clé
Survival, Therapy, Radiotherapy, Recurrence, Apoptosis, VEGFR-2, Cells
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/07/2010 15:48
Dernière modification de la notice
20/08/2019 13:43
Données d'usage